The Massachusetts General Hospital Acute Stroke Imaging Algorithm: An Experience and Evidence Based Approach by Gonzalez, Ramon Gilberto et al.
 
The Massachusetts General Hospital Acute Stroke Imaging
Algorithm: An Experience and Evidence Based Approach
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Gonzalez, Ramon Gilberto, William Alan Copen, Pamela
Whitney Schaefer, Michael Howard Lev, Stuart R. Pomerantz,
Otto Rapalino, John Wen-Yueh Chen, et al. 2013. The
Massachusetts General Hospital acute stroke imaging algorithm:
An experience and evidence based approach. Journal of
Neurointerventional Surgery 5(Suppl 1): i7-i12.
Published Version doi:10.1136/neurintsurg-2013-010715
Accessed February 19, 2015 12:05:31 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10978158
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAASUPPLEMENT
The Massachusetts General Hospital acute stroke
imaging algorithm: an experience and evidence
based approach
Ramon Gilberto González, William A Copen, Pamela W Schaefer, Michael H Lev,
Stuart R Pomerantz, Otto Rapalino, John W Chen, George J Hunter, Javier M Romero,
Bradley R Buchbinder, Mykol Larvie, Joshua Adam Hirsch, Rajiv Gupta
▸ Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
neurintsurg-2013-010715).
Neuroradiology Division,
Massachusetts General
Hospital, Harvard Medical
School, Boston,
Massachusetts, USA
Correspondence to
Dr R G González,
Neuroradiology Division,
Massachusetts General
Hospital, Harvard Medical
School, Boston, MA 02114,
USA;rggonzalez@partners.org
Received 21 February 2013
Accepted 21 February 2013
Published Online First
14 March 2013
ABSTRACT
The Massachusetts General Hospital Neuroradiology
Division employed an experience and evidence based
approach to develop a neuroimaging algorithm to best
select patients with severe ischemic strokes caused by
anterior circulation occlusions (ACOs) for intravenous
tissue plasminogen activator and endovascular treatment.
Methods found to be of value included the National
Institutes of Health Stroke Scale (NIHSS), non-contrast
CT, CT angiography (CTA) and diffusion MRI. Perfusion
imaging by CT and MRI were found to be unnecessary for
safe and effective triage of patients with severe ACOs.
An algorithm was adopted that includes: non-contrast CT
to identify hemorrhage and large hypodensity followed by
CTA to identify the ACO; diffusion MRI to estimate the
core infarct; and NIHSS in conjunction with diffusion data
to estimate the clinical penumbra.
INTRODUCTION
The purpose was to use an experience and evidence
based approach to develop the neuroimaging algo-
rithm that best improves outcomes in patients
with severe ischemic strokes caused by anterior cir-
culation occlusions (ACOs). Patients with these
strokes account for the majority of individual,
family, and societal costs due to stroke, and they
are treatable with intravenous (IV) tissue plas-
minogen activator (tPA) or/and intra-arterial
therapy (IAT). Critically evaluated was the capabil-
ity of each speciﬁc method to provide reliable infor-
mation on three key components of stroke
physiology: (1) site of arterial occlusion; (2) extent
of irreversibly injured tissue (‘infarct core’); and (3)
the size of the ischemic penumbra (ﬁgure 1).
Although varying deﬁnitions of the ischemic pen-
umbra exist, the penumbra is deﬁned herein as
severely hypoperfused brain tissue that may even-
tually be recruited into the infarct core, if not
reperfused quickly enough.
1
METHODOLOGY
The critical physiological information in the acute
stroke patient with severe symptoms is shown in
ﬁgure 1, which is a representation of a patient
with a proximal right middle cerebral artery occlu-
sion. Individual neuroradiology and neurology
faculty from the Massachusetts General Hospital
(MGH) presented the best evidence from the
literature and clinical experience on the value of
each method. Expert opinions were presented for
the National Institutes of Health Stroke Scale
(NIHSS), non-contrast CT (NCCT), CT angiog-
raphy (CTA), CTA source images (CTA-SI), diffu-
sion MRI, CT perfusion (CTP), and MRI perfusion
(MRP). Faculty and fellows who did not present
but heard the evidence, met to weigh the evidence
and make recommendations. Each modality was
assessed on two different sets of criteria shown in
tables 1 and 2. The basic practical question was: ‘Is
the modality valuable for patient care and can we
obtain it in an acute setting?’ In addition to trad-
itional metrics such as sensitivity and speciﬁcity,
the following factors were factored into the
assessments:
▸ Workﬂow. Place of the imaging test in the work-
ﬂow and does it negatively or positively affect
the workﬂow when an acute stroke patient
arrives in the emergency department.
▸ Repeatability. The values measured by the
imaging test are not affected by extraneous
parameters and repeated invocations of the test
would result in the same conclusions.
▸ Reliability. Measured values reﬂect the purported
physiologic parameter about the patient
condition.
▸ Clinical efﬁcacy. The imaging test improves
patient outcomes.
ISCHEMIC STROKE THERAPY
Intravenous tissue plasminogen activator
Intravenously administered tPA is a proven effect-
ive treatment for ischemic stroke.
2 The primary
indicators for its administration are an elapsed
time since onset of 4.5 h or less and an absence of
hemorrhage or large infarct on imaging, usually
NCCT .
Intra-arterial therapy
The target of IAT is a proximal artery occlusion.
The focus here is on major ACOs which account
for approximately 90% of all such occlusions.
3 In
patients with blockages of the intracranial internal
carotid artery (ICA) or middle cerebral artery stem
(M1 segment), two recent studies have demon-
strated the critical role of infarct volume in deter-
mining long term functional outcome (ﬁgure 2).
45
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ReviewWhen patients have large ﬁnal infarcts, there is a high likeli-
hood of signiﬁcant disability or death. It follows then that
patients presenting with extensive infarction (ie, >70–100 ml)
before treatment will have little chance for a good IAT
response.
67Moreover, studies have shown that the risk of
reperfusion hemorrhage increases with pretreatment infarct
size, and is very high (∼15%) when infarcts are larger than
100 ml.
89Therefore, risk outweighs beneﬁt in this subset of
patients. Numerous studies have conﬁrmed the importance of
core infarct size in predicting IAT outcomes.
671 0 –12 The deci-
sion to proceed to IAT therefore critically depends on the size
of the infarct core at the time of treatment, and the primary
role of imaging after identiﬁcation of a treatable occlusion is to
reliably deﬁne core infarct size accurately and precisely.
ASSESSMENT OF METHODS
National Institutes of Health Stroke Scale
The NIHSS is a Level 1/Class I test in the assessment of the
acute stroke patient.
2 It helps to quickly determine if the
patient is having a stroke and gives an indication of the severity
of the stroke. It provides a clinically relevant estimate of the
size of the ischemic tissue at risk but cannot differentiate the
core from the penumbra.
Non-contrast CT
NCCT is a Level 1/Class I test for excluding intracranial hemor-
rhage and mass lesions.
2 Because of the low sensitivity, NCCT
was scored Level 2/Class IIa to detect the infarct core volume
during the ﬁrst few hours after stroke onset. The place of
NCCT in the workﬂow and the order of imaging modalities
were also considered and it was agreed that NCCT should be
the ﬁrst test in the evaluation of acute stroke. There are excep-
tions—for example, MRI could be undertaken as the ﬁrst
imaging study in patients with poor renal function who
cannot get CTA, young patients presenting with acute stroke,
or patients more likely to have a non-ischemic etiology, such as
a mass, seizure, or migraines as the cause of their presenting
symptoms.
CT angiography
CTA is a Level 1/Class I test for the rapid assessment of large
vessel occlusion.
21 3 –15 It may also be effective for detection of
medium and small vessel occlusions, even though they can take
longer to ﬁnd. There was no concern regarding repeatability,
reliability, clinical efﬁcacy, or overall utility of CTA. It was
agreed that CTA should be performed immediately after the
NCCTscan, when feasible.
CT angiography source images
CTA-SI have been suggested as a surrogate for the infarct core.
Some older studies suggested that CTA-SI can image ischemic
core.
16 17 However, tissue density in CTA-SI is heavily depend-
ent on the scan timing, cardiac output, the rate of injection,
and the osmolality of the contrast media, among other para-
meters. For these reasons, questions were raised about the
Figure 1 Measurements of physiological components of middle
cerebral artery (MCA) occlusion. Depicted is a representation of a right
MCA occlusion with a growing infarct core coupled to a shrinking
penumbra at a rate determined by collateral ﬂow. The value of each
method used to measure each component of stroke physiology is
shown, as judged according to criteria stated in the methodology and
in tables 1 and 2. CTA, CT angiography; CTA-SI, CT angiography-source
images; CTP , CT perfusion; DWI, diffusion weighted imaging; NIHSS,
National Institutes of Health Stroke Scale.
Table 1 Massachusetts General Hospital experience and practice
based criteria
Level
1
Nearly always valuable in patient care, and successfully obtainable in the
vast majority of patients
Level
2
May be valuable in patient care, and is successfully obtainable in most
patients
Level
3
Valuable for research purposes and may or may not help in the
management of the patient
Figure 2 Relationship of ﬁnal infarct size to clinical outcomes in
patients with major anterior circulation occlusions (ACO) treated
endovascularly. The bar graphs depict the proportion of good outcomes
deﬁned as a modiﬁed Rankin Scale score of 0–2 at 3 months (blue
bars) by ﬁnal infarct volume strata. The data are from 107 patients with
ACO. The ﬁgure was derived from Yoo et al.
4
Table 2 Evidence based classification of recommendations
Class I An imaging modality for which there is evidence for and/or general
agreement that it is beneficial, useful, and effective in the management of
acute stroke
Class II An imaging modality for which there is conflicting evidence and/or
divergence of opinion about the usefulness/efficacy in the management of
acute stroke
Class
IIa
Weight of evidence or opinion is in favor of the usefulness or efficacy of
this imaging modality
Class
IIb
The usefulness or efficacy is less well established by the evidence or
expert opinion
Class III An imaging test for which there is evidence and/or general agreement that
it is not useful or effective, and in some cases may be harmful, in the
management of acute stroke patients
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Reviewrepeatability and reliability of CTA-SI in measuring tissue per-
fusion. Overall, CTA-SI was judged to be a Level 2/Class III
examination in eliciting the core of an ischemic infarct.
Diffusion MRI
Diffusion MRI is a Level 1/Class I test for the early detection
of infarct core. Diffusion weighted imaging (DWI) is nearly
100% sensitive and speciﬁc in diagnosing acute stroke
18–25
although it is not perfect in identifying the infarct core.
Positron emission tomography (PET) studies have shown that
some non-viable tissue occasionally may not demonstrate
restricted diffusion
26 27 Also, DWI abnormalities are sometimes
reversible.
28–33 However, reversal of a DWI abnormality is
unusual.
34 7 When DWI reversal does occur, it usually involves
only a small part of the lesion.
35 Also, most of the time, the
apparent DWI reversal is actually a pseudo-reversal, in that the
tissue involved proceeds to infarction anyway.
73 13 3
Perfusion imaging
Brain perfusion imaging provides information on cerebral
hemodynamics imbedded in parameters such as cerebral blood
ﬂow (CBF), cerebral blood volume (CBV), and mean transit
time (MTT). Perfusion imaging may provide many types of
important information in the care of acute stroke patients.
36 37
Additionally, much research has been devoted to demonstrating
that perfusion imaging can identify the core and penumbra,
and that perfusion imaging is useful for identifying patients
with major ACOs that are suitable for interventional
therapy.
23 83 9However, evidence based reviews have ques-
tioned this.
24 04 1
Perfusion imaging: theoretical considerations
Perfusion imaging studies the hemodynamic status of the brain
at one instant in time, and there is no instantaneous hemo-
dynamic state that uniquely characterizes the infarct core. The
hemodynamic response of the brain to ischemia has been char-
acterized with respect to cerebral perfusion pressure, and perfu-
sion parameters are summarized in ﬁgure 3 (and in more detail
in the online supplementary appendix ﬁgure A1). The autore-
gulatory vasodilation in response to reductions in regional cere-
bral perfusion pressure would be expected to result in
increased, rather than decreased, CBV in ischemic tissue.
Indeed, CBV may be elevated more often than reduced in the
infarct core.
42 More recent proposals have suggested that
regions of sufﬁciently reduced CBF may be labeled as infarct
core. This approach has greater pathophysiologic validity in
that CBF reﬂects the rate of delivery of oxygen and glucose to
brain tissue, and reductions in this rate of delivery are respon-
sible for ischemic cell death. However, neither CBF nor any
other hemodynamic measurement could ever be used to iden-
tify the core. Even complete cessation of blood ﬂow can persist
for several minutes without causing irreversible damage.
Obviously, perfusion imaging demonstrates no evidence of
ongoing perfusion impairment in reperfused tissue.
There are several hemodynamic measurements that are time
related with no direct relationship to threats to tissue viability.
For example, one of these measurements, Tmax, reﬂects the
time that elapses between arrival of blood in an index artery
and its arrival in brain tissue. A delay in the arrival of blood
does not directly threaten tissue survival. MTT measures the
average amount of time that blood spends in brain tissue,
which is usually prolonged in underperfused brain tissue. In
the setting of proximal ACO, blood must reach the tissue bed
via collateral pathways whose increased circuitry would be
expected to result in delayed arrival—that is, increased Tmax.
Also, occlusion of a proximal artery would be expected to
result in at least some reduction in distal perfusion pressure,
which would cause compensatory vasodilation in some of the
downstream tissue. This vasodilation by itself should result in
prolongation of MTT .
Thus patients with major ACO may or may not have large
regions with reduced CBF but virtually all of these patients
will demonstrate large regions of MTT and Tmax elevation.
Empirically, we have shown this to be the case, as demon-
strated in the online supplementary appendix ﬁgure A2.
43 44 In
general, the existence of a large region with increased Tmax
and MTT may be inferred from the existence of a proximal
artery occlusion on CTor MR angiographic imaging alone.
CT perfusion
Several issues and concerns about CTP were raised in addition
to radiation exposure. These concerns—which are related to
the workﬂow, process of obtaining CTP maps, and the utility
of the information derived from a CTP study—are summarized
below.
CTP process and workﬂow
There is a lack of clear guidelines on when CTP should be per-
formed, and how it should be interpreted. There was broad
agreement that:
▸ Quantiﬁcation of perfusion using CTP is not validated.
▸ There is high inter-vendor variability.
▸ There is high intra-vendor variability based on the software
version used.
▸ The variability in CTP maps is as yet unquantiﬁed with
respect to the variations in heart rate, blood pressure, ejec-
tion fraction, rate of infusion, osmolality of IV contrast,
rotation time, and temporal resolution of the scanner.
45
▸ The efﬁcacy of CTP in improving patient outcomes is
unproven.
Studies performed at MGH directly comparing core volumes
by DWI and CTP in patients with severe strokes with ACOs
Figure 3 Changes in hemodynamic parameters that may occur in
major anterior circulation occlusions. The change in cerebral perfusion
pressure (CPP) may or may not be fully compensated by the collateral
circulation. In each of the four scenarios, arrows indicate possible
increase or decrease in cerebral blood volume (CBV), cerebral blood
ﬂow (CBF), mean transit time (MTT) and Tmax. This is a derivation of
the more detailed graph shown in the online supplementary appendix
ﬁgure A1.
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two methods. However, while there is good correlation in a
population, there is a wide clinically relevant discordance
between DWI and CTP derived core volumes in individual
patients (see online supplementary appendix ﬁgure A3).
The above considerations led to the following guidelines on
the use of CTP.
▸ CTP is a Level 3/Class IIb method for early estimation of
the infarct core in acute stroke patients. Because CTP is
unable to adequately estimate the core, it necessarily
follows that it is a Level 3/Class IIb method for estimation
of the penumbra.
▸ CTP has no proven role in selecting ACO patients for IV
thrombolysis or endovascular therapy. Its roles should be
limited to:
– Research patients
– Patients who cannot get a diffusion weighted MRI
– Perfusion data could be used for other purposes such as
hypertensive therapy. However, there are scant data on
this application.
MR perfusion
MRP was deemed preferable to CTP because there is no radi-
ation exposure and it has a generally superior workﬂow.
However, the repeatability, reliability, and clinical efﬁcacy of
MRP raise similar concerns to those of CTP, including:
▸ Quantiﬁcation using MR perfusion maps is not validated.
▸ There is high inter-vendor variability.
▸ The variability of MRP maps with respect to physiologic
variables (eg, heart rate, blood pressure, ejection fraction)
and scan parameters (eg, rate of infusion, osmolality of IV
contrast, rotation time, etc) is unknown.
Carroll and colleagues
46 performed a Bland–Altman analysis
of eight smokers who were imaged with MRP and H2
15O PET
and concluded that “Until reproducibility is improved, MR is
not suitable for reliable quantitative perfusion measurements”.
Other research assessing the reliability of MRP was also
reviewed. For example, Takasawa and colleagues
47 studied per-
fusion MR (deconvolution method) and PET in ﬁve patients,
back to back, at a mean time interval of 16 h after stroke onset.
The authors concluded that “MRP appears sufﬁciently reliable
for clinical purposes”. However, most participants deliberating
on the value of the methods thought that reliability does not
override the concerns regarding high variability and low
repeatability.
Overall, MRP was judged to be a Level 3/Class IIb technique
in the management of acute stroke. There was broad agreement
that:
▸ MRP has no proven role in selecting ACO patients for endo-
vascular therapy. There is preliminary evidence that it may
improve patient selection for intravenous thrombolysis but
this evidence is currently insufﬁcient to justify MRP’s clin-
ical use in this role.
▸ Clinical indications for MRP may include:
– Research patients
– If perfusion data are deemed essential for evaluating the
full clinical picture
– When perfusion data can be used for other purposes such
as hypertensive therapy, although there are few data on
this.
The clinical penumbra
The evidence supports that the clinical penumbra, as measured
by a combination of the NIHSS and the core determined by
DWI, is the best indicator of a poor outcome in the absence of
timely reperfusion. The Prolyse in Acute Cerebral
Thromboembolism II trial demonstrated that patients with
NIHSS scores <10 did not derive a clinical beneﬁtf r o mI A T .
48
This is due to the relatively good natural history in this subset
of patients.
49 Approximately one-third of the middle cerebral
artery M1 segment occlusions present with such low scores.
50
The evidence best supports the following deﬁnition of a clinic-
ally signiﬁcant penumbra: (1) major anterior circulation (ICA
terminus or M1) occlusion; (2) NIHSS score >10; and (3) small
core infarct size (DWI lesion volume <70). Both NIHSS and
DWI are Level 1/Class I tests; together it is judged to be a Level
1/Class I method to assess the clinically relevant penumbra.
THE MGH STROKE IMAGING ALGORITHM
Based on the conclusions of the evaluation committee on the
value of each method delineated above, a new imaging algo-
rithm was proposed and adopted. A diagram of the algorithm
is shown in ﬁgure 4. Brieﬂy, all patients presenting with a
stroke syndrome receive a neurological evaluation, including the
NIHSS. NCCT is performed followed by CTA. If NCCT does
not demonstrate hemorrhage or large hypodensity, and the
patient is within the time window, tPA is prepared while the
Figure 4 Massachusetts General Hospital acute stroke imaging
algorithm for triage of patients with severe ischemic strokes caused by
anterior circulation occlusions. All patients undergo non-contrast CT
(NCCT) followed by CT angiography (CTA). If the patient has severe
neurological deﬁcits (National Institutes of Health Stroke Scale score
≥10), no large hypodensity and no hemorrhage on NCCT, and an
occlusion is identiﬁed of the distal internal carotid artery and/or
proximal middle cerebral artery that is accessible by microcatheter,
then the patient is immediately evaluated by diffusion MRI if there are
no contraindications to MRI. If the diffusion weighted imaging (DWI)
lesion is small, deﬁned as <70 ml, then the patient is immediately
triaged to endovascular therapy if the patient is otherwise eligible for
such treatment. If the patient is not eligible for MRI, he/she may
undergo a CT perfusion study for possible guidance for therapy or for
prognostic information. Also, if the patient is not eligible for
endovascular therapy, CT or MR perfusion may be performed for similar
reasons. Only the ﬁrst step in this algorithm (NCCT) and the time from
stroke onset are needed for the decision to treat with intravenous
tissue plasminogen activator. IA, intra-arterial.
i10 J NeuroIntervent Surg 2013;5:i7–i12. doi:10.1136/neurintsurg-2013-010715
ReviewCTA is performed, and infusion begins once it is prepared. If
the patient has a distal ICA and/or proximal middle cerebral
artery occlusion, he/she is moved to the MRI scanner where
diffusion MRI is performed. If the DWI lesion is small
(<70 ml), the patient is sent for IAT if the additional clinical
and medical criteria are met. Perfusion imaging with CT or
MRI may be performed if these conditions are not met, the
patient cannot be scanned by MRI, or is not otherwise eligible
for IAT and there is relevant clinical information that may be
provided by the perfusion data.
After the algorithm was adopted, there was a signiﬁcant
decline in the number of perfusion CTexaminations performed,
as shown in the online supplementary appendix ﬁgure A4.
From 40–50 CTP examinations per month in stroke patients
performed during the peak years of 2005–2008, it fell to
approximately 10 per month. There has been no discernible
effect on patient outcomes.
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